Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting(R) 2025 Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET GlobeNewswire November 07, 2025 BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) — Atea […]

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting(R) GlobeNewswire November 07, 2025 – Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) —

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire November 07, 2025 BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Vor Bio to Participate in Upcoming Investor Conferences GlobeNewswire November 07, 2025 BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: TD Cowen Virtual Immunology & Inflammation SummitFireside Chat: Wednesday, November

ESET to aid MSPs by integrating with ConnectWise Asio GlobeNewswire November 07, 2025 The ESET PROTECT console plugin for ConnectWise Asio opens up more options for MSPs. This integration empowers MSPs with better tools to perform their most common tasks more easily, saving them time while improving their legal and insurance requirements. MSP customers benefit

Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies GlobeNewswire November 07, 2025 Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Dr. Adrian Bot, a renowned biopharmaceutical founder and scientist, has joined Immuthera's Board

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review GlobeNewswire November 07, 2025 ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting GlobeNewswire November 07, 2025 Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the surface of infected hepatocytes

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025 GlobeNewswire November 07, 2025 The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS (Vafidemstat) Received feedback from the FDA on Phase III PORTICO-2 trial in

Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting(R) 2025 GlobeNewswire November 07, 2025 – Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups – – In addition to robust liver-centric effects, HU6